Consistent with the studies herein, GSK3β inhibition attenuates inflammation in preclinical disease models, including models of Alzheimer’s disease, psoriasis, and cardiomyopathy (32). The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.